Goldman Sachs
TBRA

Goldman Sachs’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

Goldman Sachs’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-28,766
Closed -$278K – 7554
2015
Q3 		$278K Sell
28,766
-30,110
-51% -$423K ﹤0.01% 5687
2015
Q2 		$1.02M Buy
58,876
+56,979
+3,004% +$833K ﹤0.01% 4530
2015
Q1 		$21K Buy
1,897
+416
+28% +$4.47K ﹤0.01% 6899
2014
Q4 		$12K Sell
1,481
-777
-34% -$6.69K ﹤0.01% 7032
2014
Q3 		$23K Sell
2,258
-386
-15% -$7.63K ﹤0.01% 6975
2014
Q2 		$162K Sell
2,644
-1,449
-35% -$88.1K ﹤0.01% 6349
2014
Q1 		$461K Sell
4,093
-1,161
-22% -$81.5K ﹤0.01% 5359
2013
Q4 		$226K Buy
5,254
+2,244
+75% +$105K ﹤0.01% 5887
2013
Q3 		$181K Buy
+3,010
New +$158K ﹤0.01% 5937

Other funds holding TBRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Goldman Sachs's TBRA Position: Q4 2015 in Review

Goldman Sachs sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2015, closing a stake of 28,766 shares — an estimated $278K sold.

Goldman Sachs first reported a position in TBRA in Q3 2013 and held it in 9 quarters. The position peaked at $1.02M in Q2 2015. 48 funds tracked by Wall St. Rank hold TBRA as of Q4 2015.

  • Goldman Sachs reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Goldman Sachs sold 28,766 Tobira Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $278K.
  • Goldman Sachs first reported a position in Tobira Therapeutics, Inc. Common Stock in Q3 2013 and held it in 9 quarters.
  • Goldman Sachs's Tobira Therapeutics, Inc. Common Stock position peaked at $1.02M in Q2 2015.
  • 48 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Goldman Sachs's 13F filing for Q4 2015, filed 16 Feb 2016.